Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the…
Primary source cited
Last reviewed
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…
Primary source cited
Last reviewed
In the randomized, phase 3 BRUIN-CLL-321 trial, pirtobrutinib -- the first and only non-covalent (reversible) BTK inhibitor -- significantly extended progression-free survival compared with standard chemoimmunotherapy options in patients with…
Primary source cited
Last reviewed
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
ClinicalTrials.gov — NCT04269902. NCT04269902.
Eligibility varies — review trial criteria.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
ClinicalTrials.gov — NCT07223190. NCT07223190.
Eligibility varies — review trial criteria.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
ClinicalTrials.gov — NCT06852222. NCT06852222.
Eligibility varies — review trial criteria.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
ClinicalTrials.gov — NCT07211958. NCT07211958.
Eligibility varies — review trial criteria.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
ClinicalTrials.gov — NCT06973187. NCT06973187.
Eligibility varies — review trial criteria.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
ClinicalTrials.gov — NCT06943872. NCT06943872.
Eligibility varies — review trial criteria.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
ECOG-ACRIN E1910 trial primary results: blinatumomab in MRD-negative B-cell precursor ALL (NEJM). DOI 10.1056/NEJMoa2312948, PMID 39047240.
Applies to the exact indication stated.
Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy (Blood, ASH Annual Meeting). DOI 10.1182/blood-2024-198541.
Applies to the exact indication stated.
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (Journal of Clinical Oncology). DOI 10.1200/JCO-25-00166, PMID 40479620.
Applies to the exact indication stated.
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…
Primary source cited
Last reviewed
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.